Multidrug-resistant tuberculosis
India: Mumbai TB Symposium Focuses on Advancing TB Treatment and Collaboration
MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics
TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries
MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
Urgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB
Global TB Report 2022: MSF calls for scale up of shorter and safer DR-TB treatments to help save more lives
Tuberculosis: Clinical trial results offer hope to DR-TB patients with short, effective treatment
